top of page
We wish to welcome our new Meitar-MSc students!
Gili, Oz and Shir!
Gili’s project is directed towards engineering novel inhibitors for well-established chemical targets in cancer therapy - Matrix Metalloproteinases (MMPs).
Oz develops a normalization approach to convert next generation sequencing results (obtained from protein library affinity sorts) to Ki (protease inhibition constants) values, and tests the approach on a held-out test set of APPI mutants complexed with mesotrypsin and KLK6.
Shir is focused on developing nanobodies (Nbs), derived from camel, against Receptor Tyrosine Kinases HER2/HER3 heterodimer, function as an oncogenic unit and initiate signaling pathways to promote tumor cell survival, by forming a heterodimer through interactions between their extracellular dimerization arms, TM, and c-terminal domains.
bottom of page